(VIANEWS) – Simulations Plus (SLP), Verisk Analytics (VRSK), ICON plc (ICLR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Simulations Plus (SLP)
10.7% sales growth and 6.16% return on equity
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California.
Earnings Per Share
As for profitability, Simulations Plus has a trailing twelve months EPS of $0.52.
PE Ratio
Simulations Plus has a trailing twelve months price to earnings ratio of 90.48. Meaning, the purchaser of the share is investing $90.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.16%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Apr 26, 2024, the estimated forward annual dividend rate is 0.24 and the estimated forward annual dividend yield is 0.51%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 16.2%, now sitting on 64.67M for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 5% and positive 750% for the next.
2. Verisk Analytics (VRSK)
7.2% sales growth and 431.9% return on equity
Verisk Analytics, Inc. provides data analytics and technology solutions to the insurance markets in the United States and internationally. It offers policy language, prospective loss costs, policy writing and rating rules, and various underwriting solutions for risk selection and segmentation, pricing, and workflow optimization; property- and auto- specific rating and underwriting information solutions that allows clients to understand, quantify, underwrite, mitigate, and avoid potential loss for risks; catastrophe modeling solutions, which enables companies to identify, quantify, and plan for the financial consequences of catastrophes for use by insurers, reinsurers, intermediaries, financial institutions, and governments. The company also provides life insurance solutions for transforming current workflows in life insurance underwriting, claim insights, policy administration, unclaimed property/equity, compliance and fraud detection, and actuarial and portfolio modeling; Marketing Solutions, such as compliant, real-time decisioning, profitability, and risk assessment for inbound consumer interactions; and international underwriting and claims solutions. In addition, it offers claims insurance solutions, which provides analytics in fraud detection, compliance reporting, subrogation liability assessment, litigation, and repair cost estimation and valuation solutions; and casualty solutions, such as compliance, casualty claims decision support, and workflow automation solutions. Further, the company supplies software to the specialty insurance market. The company was founded in 1971 and is headquartered in Jersey City, New Jersey.
Earnings Per Share
As for profitability, Verisk Analytics has a trailing twelve months EPS of $5.23.
PE Ratio
Verisk Analytics has a trailing twelve months price to earnings ratio of 42.55. Meaning, the purchaser of the share is investing $42.55 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 431.9%.
3. ICON plc (ICLR)
6.5% sales growth and 7.55% return on equity
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; and clinical research services, including biostatistics, clinical operations, clinical supplies management, covid-19, data management, decentralized & hybrid clinical solutions, endpoint adjudication services, interactive response technologies, investigator payments, medical affairs, medical writing and publishing, pharmacovigilance, and site and patient solutions. The company also provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. In addition, it offers commercial positioning, early phase, language, medical imaging, and strategic solutions, as well as clinical trial management, consulting, and contract staffing services. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, ICON plc has a trailing twelve months EPS of $8.24.
PE Ratio
ICON plc has a trailing twelve months price to earnings ratio of 39.26. Meaning, the purchaser of the share is investing $39.26 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.55%.
Yearly Top and Bottom Value
ICON plc’s stock is valued at $323.49 at 11:22 EST, under its 52-week high of $344.77 and way higher than its 52-week low of $219.00.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.7%, now sitting on 8.23B for the twelve trailing months.
Sales Growth
ICON plc’s sales growth for the next quarter is 6.5%.
4. HealthStream (HSTM)
5.2% sales growth and 5.23% return on equity
HealthStream, Inc. provides Software-as-a-Service (SaaS) based applications for healthcare organizations in the United States. The company's solutions help healthcare organizations in meeting their ongoing clinical development, talent management, training, education, assessment, competency management, safety and compliance, and scheduling, as well as provider credentialing, privileging, and enrollment needs. It offers hStream, a technology platform that powers a range of healthcare workforce solutions. The company provides its solutions to customers across a range of entities within the healthcare industry, including private, not-for-profit, and government entities, as well as pharmaceutical and medical device companies through its direct sales teams. The company was incorporated in 1990 and is headquartered in Nashville, Tennessee.
Earnings Per Share
As for profitability, HealthStream has a trailing twelve months EPS of $0.58.
PE Ratio
HealthStream has a trailing twelve months price to earnings ratio of 47.36. Meaning, the purchaser of the share is investing $47.36 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.23%.
Sales Growth
HealthStream’s sales growth is 5.3% for the ongoing quarter and 5.2% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.5%, now sitting on 282.88M for the twelve trailing months.
